Headlines about Vertex Pharmaceuticals (NASDAQ:VRTX) have been trending somewhat positive this week, according to Alpha One Sentiment Analysis. The research group, a unit of Accern, identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Vertex Pharmaceuticals earned a media sentiment score of 0.12 on Alpha One’s scale. Alpha One also gave media coverage about the pharmaceutical company an impact score of 77 out of 100, indicating that recent news coverage is likely to have an impact on the company’s share price in the next several days.
Here are some of the news headlines that may have effected Alpha One Sentiment’s analysis:
- How Analysts Rated Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Last Week? (trikkles.com)
- The Vertex Pharmaceuticals Incorporated (VRTX) Shares Sold by KBC Group NV (leisuretravelaid.com)
- Vertex Pharmaceuticals Up 60.1% Since SmarTrend Uptrend Call (VRTX) (mysmartrend.com)
- Vertex shares soar in 2017, and the best may be yet to come (finance.yahoo.com)
- Vertex Names Dr. Alan Garber, Provost of Harvard University, to its Board of Directors (finance.yahoo.com)
Shares of Vertex Pharmaceuticals (VRTX) traded down 1.41% during mid-day trading on Friday, reaching $124.14. 841,807 shares of the company’s stock traded hands. The stock has a 50-day moving average price of $119.25 and a 200 day moving average price of $96.29. The firm has a market capitalization of $30.92 billion, a price-to-earnings ratio of 173.14 and a beta of 0.79. Vertex Pharmaceuticals has a 12-month low of $71.46 and a 12-month high of $130.69.
Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Thursday, April 27th. The pharmaceutical company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.09. Vertex Pharmaceuticals had a negative net margin of 6.76% and a negative return on equity of 2.15%. The business had revenue of $714.72 million during the quarter, compared to analysts’ expectations of $692.64 million. During the same period last year, the business earned $0.09 earnings per share. The business’s revenue for the quarter was up 79.5% on a year-over-year basis. Analysts anticipate that Vertex Pharmaceuticals will post $1.66 EPS for the current fiscal year.
A number of research firms recently commented on VRTX. Oppenheimer Holdings Inc. reissued a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Sunday, April 30th. Maxim Group set a $143.00 target price on Vertex Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, May 19th. Cowen and Company set a $75.00 target price on Vertex Pharmaceuticals and gave the company a “hold” rating in a research note on Saturday, February 11th. JMP Securities reissued an “outperform” rating and issued a $127.00 target price (up previously from $125.00) on shares of Vertex Pharmaceuticals in a research note on Friday, May 19th. Finally, Vetr raised Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and set a $119.50 target price on the stock in a research note on Tuesday, May 30th. Nine analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $117.02.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Press Coverage Likely to Impact Vertex Pharmaceuticals (VRTX) Stock Price” was first reported by sleekmoney and is the property of of sleekmoney. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://sleekmoney.com/somewhat-positive-press-coverage-likely-to-impact-vertex-pharmaceuticals-vrtx-stock-price/1895882.html.
In other Vertex Pharmaceuticals news, CEO Jeffrey M. Leiden sold 157,200 shares of Vertex Pharmaceuticals stock in a transaction dated Friday, April 28th. The shares were sold at an average price of $119.50, for a total transaction of $18,785,400.00. Following the completion of the sale, the chief executive officer now directly owns 395,152 shares in the company, valued at $47,220,664. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Amit Sachdev sold 80,500 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, March 29th. The shares were sold at an average price of $107.63, for a total transaction of $8,664,215.00. Following the sale, the executive vice president now owns 105,054 shares of the company’s stock, valued at $11,306,962.02. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 499,175 shares of company stock valued at $60,610,079. Company insiders own 1.90% of the company’s stock.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/somewhat-positive-press-coverage-likely-to-impact-vertex-pharmaceuticals-vrtx-stock-price/1895882.html
Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.